Broadly Neutralizing Monoclonal Antibody against Multiple Influenza A H5Nx cladesTechnology #13398n
Questions about this technology? Ask a Technology Manager
Broadly Neutralizing Monoclonal Antibody against Multiple Influenza A H5Nx clades
Highly pathogenic avian influenza A (HPAI) virus H5N1 remains a serious threat to global health due to its unabated and widespread geographical circulation. WHO reported a high mortality rate of H5N1 infection – 59%. Although human cases remain sporadic, the absence of human herd immunity, the high lethality, and potential ability of HPAI H5N1 to gain efficient human transmissibility all point towards a potentially catastrophic pandemic. The highly evolving nature of H5N1 viruses has led to the evolution of diverse lineages with distinct geographical distribution. Since 2008, it was also found that H5N1 virus had undergone reassortment with other circulating virus of different subtypes to give rise to several new viruses, which are collectively known H5Nx viruses. Of these, the newly emerged H5N6 reassortant virus is of particular concern because of spreading over a wide geographic area in Southeast Asia and several cases of infection in humans in China with one fatality being reported. Such diversity challenges the efficacy of vaccination strategies. It is also worrying that some human and avian isolates of H5N1 have been shown to be resistant to the two main classes of anti-influenza A virus drugs, namely neuraminidase inhibitors and adamantanes.
The NUS researchers have developed a chimeric antibody with potent neutralizing activity across multiple influenza A H5Nx clades. The antibody neutralizes 6 different H5N1 strains from different areas, representative of 2 different clades and 7 years of evolution of the virus. Recent study shows that the antibody also neutralizes the recent 2014 H5N6 virus.
Prophylactic and therapeutic treatment against influenza A H5Nx infection
The antibody has potent neutralizing
activity against multiple influenza A H5N1 clades, and provides prophylactic
and therapeutic protection. in
The antibody has been shown to neutralize
recently emerged H5N6 virus. It may have the potential to neutralize newly
emerging H5Nx strains.
The binding epitope on hemagglutinin (HA)
is distinct from other known monoclonal antibodies that bind to similar part of
HA. Thus it could be used in combination with other monoclonal antibodies or
anti-viral drugs in a combination therapy.
Available for licensing. Patent pending in US and Europe.
Dr. Chenning Lu
NUS ILO Ref No: 13398N
A/Prof. Yee-Joo Tan